The disclosure relates to medical devices and in particular to devices and methods that generate and deliver therapeutic treatment pulses used in medical devices, such as cardioverters and defibrillators, neuro-stimulators, musculo-skeletal stimulators, organ stimulators and nerve stimulators. More specifically the disclosure relates to the generation and delivery/use by such medical devices of a new and innovatively shaped biphasic or multiphasic pulse waveform.
It is well known that a signal having a waveform may have a therapeutic benefit when the signal is applied to a patient. For example, the therapeutic benefit to a patient may be a treatment that is provided to the patient. The therapeutic benefit or therapeutic treatment may include stimulation of a part of the body of the patient or treatment of a sudden cardiac arrest of the patient. Existing systems that apply a signal with a waveform to the patient often generate and apply a well-known signal waveform and do not provide much, or any, adjustability or variability of the signal waveform.
In the context of defibrillators or cardioverters, today's manual defibrillators deliver either an older style Monophasic Pulse (a single high energy single polarity pulse) or the now more common Biphasic Pulse (consisting of an initial positive high energy pulse followed by a smaller inverted negative pulse). Today's implantable cardioverter defibrillators (ICDs), automated external defibrillators (AEDs) and wearable cardioverter defibrillators (WCDs) all deliver Biphasic Pulses with various pulse phase lengths, high initial starting pulse amplitude and various pulse slopes. Each manufacturer of a particular defibrillator, for commercial reasons, has their own unique and slightly different exact timing and shape of the biphasic pulse for their devices' pulses, although they are all based off of the standard biphasic waveform design. Multiple clinical studies over the last couple of decades have indicated that use of these variants of the biphasic waveform has greater therapeutic value than the older monophasic waveform does to a patient requiring defibrillation therapy and that these standard biphasic waveforms are efficacious at appreciably lower levels of energy delivery than the original monophasic waveforms, and with a higher rate of resuscitation success on first shock delivery.
Thus, almost all of the current defibrillator products that use a biphasic waveform pulse have a single high-energy reservoir, which, while simple and convenient, results in severe limitation on the range of viable pulse shapes that can be delivered. Specifically, the second (or Negative) phase of the Biphasic waveform is currently characterized by a lower amplitude starting point than the first (or Positive) phase of the Biphasic waveform, as shown in
The standard biphasic pulse waveform has been in common usage in manual defibrillators and in AEDs since the mid-1990s, and still results in energy levels of anywhere from 120 to 200 joules or more being delivered to the patient in order to be efficacious. This results in a very high level of electrical current passing through the patient for a short period of time which can lead to skin and flesh damage in the form of burns at the site of the electrode pads or paddles in addition to the possibility of damage to organs deeper within the patient's body, including the heart itself. The significant amounts of energy used for each shock and the large number of shocks that these AED devices are designed to be able to deliver over their lifespan, has also limited the ability to further shrink the size of the devices.
WCDs generally need to deliver shocks of 150-200 joules in order to be efficacious, and this creates a lower limit on the size of the electrical components and the batteries required, and hence impacts the overall size of the device and the comfort levels for the patient wearing it.
ICDs, given that they are implanted within the body of patients, have to be able to last for as many years as possible before their batteries are exhausted and they have to be surgically replaced with a new unit. Typically ICDs deliver biphasic shocks of up to a maximum of 30-45 joules, lower than is needed for effective external defibrillation as the devices are in direct contact with the heart tissue of the patient. Subcutaneous ICDs, differ slightly in that they are not in direct contact with the heart of the patient, and these generally deliver biphasic shocks of 65-80 joules in order to be efficacious. Even at these lower energy levels there is significant pain caused to the patient if a shock is delivered in error by the device. Most existing devices are designed to last for between 5-10 years before their batteries are depleted and they need to be replaced.
Another, equally common type of defibrillator is the Automated External Defibrillator (AED). Rather than being implanted, the AED is an external device used by a third party to resuscitate a person who has suffered from sudden cardiac arrest.
A typical protocol for using the AED 800 is as follows. Initially, the person who has suffered from sudden cardiac arrest is placed on the floor. Clothing is removed to reveal the person's chest 808. The pads 804 are applied to appropriate locations on the chest 808, as illustrated in
The disclosure is applicable to various medical devices including all defibrillator types: external (manual, semi-automated, and fully automated), wearable, implantable and subcutaneous implantable. In addition to defibrillators, the medical device may also be cardioverters and external/internal pacers, as well as other types of electrical stimulation medical devices, such as: neuro-stimulators, musculo-skeletal stimulators, organ stimulators and nerve/peripheral nerve stimulators, whether the devices are external or implantable. The novel biphasic or multiphasic waveform generator may be particularly useful for any type of defibrillator and examples of the novel biphasic or multiphasic waveform generator system will be described in the context of a defibrillator for illustration purposes. It will be appreciated, however, that the novel biphasic or multiphasic waveform generator may generate and deliver a much wider range of waveforms than has previously been possible in the art (or as shown in the examples) including a new generation/family of novel biphasic or multiphasic waveforms, as shown in
The novel biphasic or multiphasic waveform generator can be embodied in a number of different ways, constituting a range of different potential circuit designs all of which are within the scope of this disclosure since any of the circuit designs would be able to generate and deliver a wide range of biphasic and/or multiphasic waveforms including the new family/generation of low energy biphasic and/or multiphasic waveforms where the first phase of the waveform has a lower amplitude than the second phase of the waveform.
The medical device system 100 may include a medical device 102 that generates and delivers a novel biphasic or multiphasic pulse waveform 110 to a patient 112. The novel biphasic or multiphasic pulse waveform 110 may be a therapeutic pulse, a defibrillation pulse and the like. As shown in
The novel biphasic or multiphasic pulse waveform 110 may have one or more first phases and one or more second phases wherein the first and second phases may be opposite polarities. In one biphasic waveform example, the first phase may be a positive phase, the second phase may be a negative phase and the second phase of the waveform may be larger in amplitude than the amplitude of the first phase of the waveform as shown in
The control logic unit 108 may be coupled to and/or electrically connected to the multiphasic or biphasic waveform generator 104 and the energy source 106 to control each of those components to generate various version of the biphasic or multiphasic pulse waveform 110. The energy source 106 may be one or more power sources and one or more energy reservoirs. The control logic unit 108 may be implemented in hardware. For example, the control logic unit 108 may be a plurality of lines of computer code that may be executed by a processor that is part of the medical device. The plurality of lines of computer code may be executed by the processor so that the processor is configured to control the multiphasic or biphasic waveform generator 104 and the energy source 106 to generate the biphasic or multiphasic pulse waveform 110. In another embodiment, the control logic unit 108 may be a programmable logic device, application specific integrated circuit, a state machine, a microcontroller that then controls the multiphasic or biphasic waveform generator 104 and the energy source 106 to generate the biphasic or multiphasic pulse waveform 110. The control logic unit may also include analog or digital switching circuitry when the high voltage switching component 109 is part of the control logic unit 108.
As shown in
The energy source 106 is not limited to any particular number of energy reservoirs (such as capacitors) or energy sources (such as batteries). Thus, the medical device system 10 may have a plurality or “n” number (as many as wanted) of subsystems 12, 14 that together can be utilized to generate the various multiphasic or biphasic waveforms. In the example embodiments shown in
Each subsystem 12, 14 of each side, as shown in
In another embodiment (see
In another embodiment (see
Another embodiment of the system makes use of a direct current generation source in order to generate the initial phase of the waveform and then uses one or more reservoirs of stored electrical energy in order to generate the second phase of the waveform and any additional phases of the waveform. The energy reservoirs used may be supplied by one or more energy sources.
Another embodiment of the system makes use of a direct current generation source in order to generate the initial phase of the waveform and then uses one or more additional direct current generation sources, configured alone, together, or else in combination with reservoirs of stored electrical energy, in order to generate the second phase of the waveform and any additional phases of the waveform. The energy reservoirs used may be supplied by one or more energy sources.
In additional embodiments, the pulse generator may be configured with the circuitry, processors, programming and other control mechanisms necessary to separately and individually vary the phase timings, the inter-phase pulse timing(s), the phase tilts and the phase amplitudes necessary to customize and optimize the waveform for the patient at hand and for the specific therapeutic purpose for which the waveform is being used.
The above described functions may be accomplished through the use of a fast switching high-energy/voltage switch system 109 which can be either analog or digital in nature or even some hybrid of the two approaches as shown in
Other embodiments of the system discharge part of the waveform's initial phase energy through the use of a statically or dynamically allocated group of resistive power splitters (see
Many embodiments of the system can make use of one or more additional circuitry modules or subsystems intended to alter the RC constant of the pulse delivery circuitry for one or more of the pulse phases, and hence alter the tilt of the phase of the pulse waveform involved. These modules or subsystems can consist of an array of capacitors or an array of resistors, or of a combination of the two (see
In some embodiments of the system, the system may provide for the recharging of individual energy reservoirs by the energy sources during times (including inter-phase pulse times) that an individual energy reservoir is not selected for discharge. This provides the opportunity to interlace equivalent amplitude initial multiphasic pulses utilizing several different high energy reservoirs.
While the foregoing has been with reference to a particular embodiment of the disclosure, it will be appreciated by those skilled in the art that changes in this embodiment may be made without departing from the principles and spirit of the disclosure, the scope of which is defined by the appended claims.
This application is a continuation in part of and claims priority under 35 USC 120 to U.S. patent application Ser. No. 14/303,541, filed on Jun. 12, 2014 and entitled “Dynamically Adjustable Multiphasic Defibrillator Pulse System And Method” which in turn claims priority to under 35 USC 120 and claims the benefit under 35 USC 119(e) of U.S. Provisional Patent Application Ser. No. 61/835,443 filed Jun. 14, 2013 and titled “Dynamically Adjustable Multiphasic Defibrillator Pulse System and Method”, the entirety of both of which are incorporated herein by reference.
Number | Name | Date | Kind |
---|---|---|---|
4441498 | Nordling | Apr 1984 | A |
5199429 | Kroll et al. | Apr 1993 | A |
5240995 | Gyory et al. | Aug 1993 | A |
5290585 | Elton | Mar 1994 | A |
5338490 | Dietz et al. | Aug 1994 | A |
5362420 | Itoh et al. | Nov 1994 | A |
5402884 | Gilman et al. | Apr 1995 | A |
5489624 | Kantner et al. | Feb 1996 | A |
5536768 | Kantner et al. | Jul 1996 | A |
5573668 | Grosh et al. | Nov 1996 | A |
5643252 | Waner et al. | Jul 1997 | A |
5658316 | Lamond et al. | Aug 1997 | A |
5660178 | Kantner et al. | Aug 1997 | A |
5733310 | Lopin et al. | Mar 1998 | A |
5800685 | Perrault | Sep 1998 | A |
5871505 | Adams | Feb 1999 | A |
5987354 | Cooper | Nov 1999 | A |
6004312 | Finneran et al. | Dec 1999 | A |
6006131 | Cooper et al. | Dec 1999 | A |
6056738 | Marchitto et al. | May 2000 | A |
6141584 | Rockwell et al. | Oct 2000 | A |
6197324 | Crittenden | Mar 2001 | B1 |
6251100 | Flock et al. | Jun 2001 | B1 |
6256533 | Yuzhakov et al. | Jul 2001 | B1 |
6266563 | Kenknight et al. | Jul 2001 | B1 |
6315722 | Yaegashi | Nov 2001 | B1 |
6329488 | Terry et al. | Dec 2001 | B1 |
6379324 | Gartstein et al. | Apr 2002 | B1 |
6477413 | Sullivan et al. | Nov 2002 | B1 |
6576712 | Feldstein et al. | Jun 2003 | B2 |
6596401 | Terry et al. | Jul 2003 | B1 |
6597948 | Rockwell et al. | Jul 2003 | B1 |
6611707 | Prausnitz et al. | Aug 2003 | B1 |
6690959 | Thompson | Feb 2004 | B2 |
6714817 | Daynes et al. | Mar 2004 | B2 |
6797276 | Glenn et al. | Sep 2004 | B1 |
6803420 | Cleary et al. | Oct 2004 | B2 |
6908453 | Fleming et al. | Jun 2005 | B2 |
6908681 | Terry et al. | Jun 2005 | B2 |
6931277 | Yuzhakov et al. | Aug 2005 | B1 |
7072712 | Kroll et al. | Jul 2006 | B2 |
7108681 | Gartstein et al. | Sep 2006 | B2 |
7215991 | Besson et al. | May 2007 | B2 |
7226439 | Prausnitz et al. | Jun 2007 | B2 |
7463917 | Martinez | Dec 2008 | B2 |
7645263 | Angel et al. | Jan 2010 | B2 |
7797044 | Covey et al. | Sep 2010 | B2 |
8024037 | Kumar | Sep 2011 | B2 |
8527044 | Edwards et al. | Sep 2013 | B2 |
8558499 | Ozaki et al. | Oct 2013 | B2 |
8615295 | Savage et al. | Dec 2013 | B2 |
8781576 | Savage et al. | Jul 2014 | B2 |
9089718 | Owen et al. | Jul 2015 | B2 |
9101778 | Savage et al. | Aug 2015 | B2 |
9616243 | Raymond et al. | Apr 2017 | B2 |
9656094 | Raymond et al. | May 2017 | B2 |
20010031992 | Fishler et al. | Oct 2001 | A1 |
20020016562 | Cormier et al. | Feb 2002 | A1 |
20020045907 | Sherman et al. | Apr 2002 | A1 |
20020082644 | Picardo et al. | Jun 2002 | A1 |
20100181069 | Sullivan et al. | Nov 2002 | A1 |
20030017743 | Picardo et al. | Jan 2003 | A1 |
20030055460 | Owen et al. | Mar 2003 | A1 |
20030088279 | Rissmann et al. | May 2003 | A1 |
20030125771 | Garrett et al. | Jul 2003 | A1 |
20030167075 | Fincke | Sep 2003 | A1 |
20030197487 | Tamura et al. | Oct 2003 | A1 |
20040105834 | Singh et al. | Jun 2004 | A1 |
20040143297 | Maynard, III | Jul 2004 | A1 |
20040166147 | Lundy et al. | Aug 2004 | A1 |
20040247655 | Asmus et al. | Dec 2004 | A1 |
20050055460 | Johnson et al. | Mar 2005 | A1 |
20050107713 | Van Herk | May 2005 | A1 |
20050123565 | Subramony et al. | Jun 2005 | A1 |
20060136000 | Bowers | Jun 2006 | A1 |
20060142806 | Katzman et al. | Jun 2006 | A1 |
20060173493 | Armstrong et al. | Aug 2006 | A1 |
20060206152 | Covey et al. | Sep 2006 | A1 |
20070016268 | Carter et al. | Jan 2007 | A1 |
20070078376 | Smith | Apr 2007 | A1 |
20070135729 | Ollmar et al. | Jun 2007 | A1 |
20070143297 | Recio et al. | Jun 2007 | A1 |
20070150008 | Jones et al. | Jun 2007 | A1 |
20070191901 | Schecter | Aug 2007 | A1 |
20080082153 | Gadsby et al. | Apr 2008 | A1 |
20080097546 | Powers et al. | Apr 2008 | A1 |
20080154110 | Burnes et al. | Jun 2008 | A1 |
20080154178 | Carter et al. | Jun 2008 | A1 |
20080177342 | Snyder | Jul 2008 | A1 |
20080312579 | Chang et al. | Dec 2008 | A1 |
20080312709 | Volpe et al. | Dec 2008 | A1 |
20090005827 | Weintraub et al. | Jan 2009 | A1 |
20090076366 | Palti | Mar 2009 | A1 |
20090210022 | Powers | Aug 2009 | A1 |
20090318988 | Powers | Dec 2009 | A1 |
20090326400 | Huldt | Dec 2009 | A1 |
20100063559 | McIntyre et al. | Mar 2010 | A1 |
20100160712 | Burnett et al. | Jun 2010 | A1 |
20100191141 | Aberg | Jul 2010 | A1 |
20100241181 | Savage et al. | Sep 2010 | A1 |
20100249860 | Shuros et al. | Sep 2010 | A1 |
20110028859 | Chian | Feb 2011 | A1 |
20110071611 | Khuon et al. | Mar 2011 | A1 |
20110208029 | Joucla et al. | Aug 2011 | A1 |
20110237922 | Parker, III et al. | Sep 2011 | A1 |
20110288604 | Kaib et al. | Nov 2011 | A1 |
20110301683 | Axelgaard | Dec 2011 | A1 |
20120101396 | Solosko et al. | Apr 2012 | A1 |
20120112903 | Kaib et al. | May 2012 | A1 |
20120136233 | Yamashita | May 2012 | A1 |
20120158075 | Kaib et al. | Jun 2012 | A1 |
20120158078 | Kaib et al. | Jun 2012 | A1 |
20120203297 | Efimov et al. | Aug 2012 | A1 |
20120259382 | Trier | Oct 2012 | A1 |
20130018251 | Caprio et al. | Jan 2013 | A1 |
20130144365 | Kipke et al. | Jun 2013 | A1 |
20140005736 | Geheb | Jan 2014 | A1 |
20140039593 | Savage et al. | Feb 2014 | A1 |
20140039594 | Savage et al. | Feb 2014 | A1 |
20140221766 | Kinast | Aug 2014 | A1 |
20140276183 | Badower | Sep 2014 | A1 |
20140277226 | Poore et al. | Sep 2014 | A1 |
20140317914 | Shaker | Oct 2014 | A1 |
20140371566 | Raymond et al. | Dec 2014 | A1 |
20140371567 | Raymond et al. | Dec 2014 | A1 |
20140371805 | Raymond et al. | Dec 2014 | A1 |
20140371806 | Raymond et al. | Dec 2014 | A1 |
20150297104 | Chen et al. | Oct 2015 | A1 |
20150327781 | Hernandez-Silveira et al. | Nov 2015 | A1 |
20160206893 | Raymond et al. | Jul 2016 | A1 |
20160213933 | Raymond et al. | Jul 2016 | A1 |
20160213938 | Raymond et al. | Jul 2016 | A1 |
20160296177 | Gray et al. | Oct 2016 | A1 |
20160361533 | Savage et al. | Dec 2016 | A1 |
20160361555 | Savage et al. | Dec 2016 | A1 |
20170252572 | Raymond et al. | Sep 2017 | A1 |
Number | Date | Country |
---|---|---|
10 2006 025864 | Dec 2007 | DE |
1 530 983 | May 2005 | EP |
1 834 622 | Sep 2007 | EP |
2005-144164 | Jun 2005 | JP |
2007-530124 | Nov 2007 | JP |
2008-302254 | Dec 2008 | JP |
2010-511438 | Apr 2010 | JP |
2010-529897 | Sep 2010 | JP |
2012-135457 | Jul 2012 | JP |
2012-529954 | Nov 2012 | JP |
2000-093526 | Jan 2017 | JP |
2011-512227 | Sep 2017 | JP |
2012-501789 | Sep 2017 | JP |
S63-296771 | Sep 2017 | JP |
WO 03020362 | Mar 2003 | WO |
WO 2010146492 | Dec 2010 | WO |
WO2010151875 | Dec 2010 | WO |
Entry |
---|
PCT International Preliminary Report on Patentability of PCT/US2010/027346 dated Sep. 20, 2011 (12 pages). |
PCT International Search Report of PCT/US10/27346; dated Oct. 14, 2010 (4 pgs.). |
PCT Written Opinion of the International Searching Authority of PCT/US10/27346; dated Oct. 14, 2010 (7 pgs.). |
PCT International Preliminary Report on Patentability of PCT/US12/65712; dated Jun. 10, 2014 (6 pgs.). |
PCT International Search Report of PCT/US2012/065712, dated Mar. 29, 2013 (2 pages). |
PCT International Search Report of PCT/US14/42355; dated Nov. 3, 2010 (2 pgs.). |
PCT Written Opinion of PCT/US2012/065712, dated Mar. 29, 2013 (5 pages). |
PCT Written Opinion of the International Searching Authority of PCT/US14/42355; dated Nov. 3, 2014 (6 pgs.). |
PCT International Search Report of PCT/US14/42356; dated Nov. 3, 2010 (2 pgs.). |
PCT Written Opinion of the International Searching Authority of PCT/US14/42356; dated Nov. 3, 2014 (6 pgs.). |
PCT International Search Report of PCT/US14/42360; dated Nov. 4, 2010 (2 pgs.). |
PCT Written Opinion of the International Searching Authority of PCT/US14/42360; dated Nov. 4, 2014 (4 pgs.). |
PCT International Search Report of PCT/US14/42409; dated Nov. 4, 2010 (2 pgs.). |
PCT Written Opinion of the International Searching Authority of PCT/US14/42409; dated Nov. 4, 2014 (4 pgs.). |
PCT International Preliminary Report on Patentability and Written Opinion of PCT/EP2007/009879; dated May 19, 2009 (7 pages). |
PCT International Search Report of PCT/EP2007/009879; dated Apr. 29, 2008 (3 pages). |
PCT International Written Opinion of PCT/EP2007/009879; dated Apr. 29, 2008 (6 pages). |
Chinese First Office Action of CN 201080021650.4 (English and Chinese); dated Jul. 24, 2013 (19 pgs.). |
Chinese Second Office Action of CN 201080021650.4 (English and Chinese); dated Jan. 16, 2014 (16 pgs.). |
Chinese Third Office Action of CN 201080021650.4 (English and Chinese); dated Jun. 17, 2014 (18 pgs.). |
Japanese Notification of Reason for Rejection of JP 2012-500855 (English and Japanese); dated Feb. 17, 2014 (3 pgs.). |
Extended European Search Report of EP 2408521 dated Jul. 10, 2012 (8 pages). |
“Changes in the passive electrical properties of human stratum corneum due electroporation” dated Dec. 7, 1994. By U. Pliquett, R. Langer, and J. C. Weaver (11 pages). |
“Electrical properties of the epidermal stratum corneum” dated Aug. 12, 1974. By T. Yamamoto and Y. Yamamoto (8 pages). |
“Non-invasive bioimpedance of intact skin: mathematical modeling and experiments” dated May 2, 2010. By U. Birgersson, E. Birgersson, P. Aberg, I. Nicander, and S. Ollmar (19 pages). |
Polymer Microneedles for Controlled-Release Drug Delivery dated Dec. 2, 2005. By J-H. Park, M. G. Allen, and M. R. Prausnitz (12 pages). |
“Utilizing Characteristic Electrical Properties of the Epidermal Skin Layers to Detect Fake Fingers in Biometric Fingerprint Systems—A Pilot Study” dated Dec. 1, 2004. By O. G. Martinsen, S. Clausen, J. B. Nysaether, and S. Grimnes (4 pages). |
“Lack of Pain Associated with Microfabricated Microneedles” dated Oct. 10, 2000. By S. Kaushik, A. H. Hord, D. D. Denson, D. V. McAlliser, S. Smitra, M. G. Allen, and M. R. Prausnitz (3 pages). |
“Two Dimensional Metallic Microelectrode Arrays for Extracellular Stimulation and Recording of Neurons” dated 1993. By A. B. Frazier, D. P. O'Brien, and M. G. Allen (6 pages). |
“Insertion of microneedles into skin: measurement and prediction of insertion force and needle facture force” dated Dec. 10, 2003. By S. P. Davis, B. J. Landis, Z. H. Adams, M. G. Allen, and M. R. Prausnitz (9 pages). |
“Microneedle Insertion Force Reduction Using Vibratory Actuation” dated 2004. By M. Yang and J D Zahn (6 pages). |
Yoshio Yamanouchi, et al., Optimal Small-Capacitor Biphasic Waveform for External Defibrillation; Influence of Phase-1 Tilt and Phase-2 Voltage, Journal of the American Heart Association, Dec. 1, 1998, vol. 98, pp. 2487-2493 (8 pgs.). |
Number | Date | Country | |
---|---|---|---|
20160213933 A1 | Jul 2016 | US |
Number | Date | Country | |
---|---|---|---|
61835443 | Jun 2013 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 14303541 | Jun 2014 | US |
Child | 14662165 | US |